Published in Development on January 15, 2013
Pluripotent stem cells in regenerative medicine: challenges and recent progress. Nat Rev Genet (2014) 2.12
Stem cell therapy. Use of differentiated pluripotent stem cells as replacement therapy for treating disease. Science (2014) 1.49
Huntingtin Subcellular Localisation Is Regulated by Kinase Signalling Activity in the StHdhQ111 Model of HD. PLoS One (2015) 1.40
Human-induced pluripotent stem cells: potential for neurodegenerative diseases. Hum Mol Genet (2014) 0.96
Activin A directs striatal projection neuron differentiation of human pluripotent stem cells. Development (2015) 0.95
Modeling Huntington's disease with induced pluripotent stem cells. Mol Cell Neurosci (2013) 0.94
Moving stem cells to the clinic: potential and limitations for brain repair. Neuron (2015) 0.94
Stem cells on the brain: modeling neurodevelopmental and neurodegenerative diseases using human induced pluripotent stem cells. J Neurogenet (2014) 0.91
Stimulation of GABA-induced Ca2+ influx enhances maturation of human induced pluripotent stem cell-derived neurons. PLoS One (2013) 0.90
Induced Pluripotent Stem Cells in Huntington's Disease Research: Progress and Opportunity. J Huntingtons Dis (2016) 0.85
A novel manganese-dependent ATM-p53 signaling pathway is selectively impaired in patient-based neuroprogenitor and murine striatal models of Huntington's disease. Hum Mol Genet (2014) 0.84
Stem and Progenitor Cell-Based Therapy of the Central Nervous System: Hopes, Hype, and Wishful Thinking. Cell Stem Cell (2016) 0.84
Differentiation of pluripotent stem cells into striatal projection neurons: a pure MSN fate may not be sufficient. Front Cell Neurosci (2014) 0.83
Concise Review: Progress and Challenges in Using Human Stem Cells for Biological and Therapeutics Discovery: Neuropsychiatric Disorders. Stem Cells (2016) 0.81
Cell-based therapies for Huntington's disease. Drug Discov Today (2014) 0.80
Organization of the human fetal subpallium. Front Neuroanat (2014) 0.80
Pluripotent stem cells as a model to study non-coding RNAs function in human neurogenesis. Front Cell Neurosci (2013) 0.79
Using human induced pluripotent stem cells to model cerebellar disease: Hope and hype. J Neurogenet (2015) 0.78
iPSC-based drug screening for Huntington׳s disease. Brain Res (2015) 0.77
Neural Differentiation of Human Pluripotent Stem Cells for Nontherapeutic Applications: Toxicology, Pharmacology, and In Vitro Disease Modeling. Stem Cells Int (2015) 0.77
Neural FoxP2 and FoxP1 expression in the budgerigar, an avian species with adult vocal learning. Behav Brain Res (2015) 0.77
Quantitative high-throughput gene expression profiling of human striatal development to screen stem cell-derived medium spiny neurons. Mol Ther Methods Clin Dev (2015) 0.77
From pluripotency to forebrain patterning: an in vitro journey astride embryonic stem cells. Cell Mol Life Sci (2014) 0.77
Current Perspective of Stem Cell Therapy in Neurodegenerative and Metabolic Diseases. Mol Neurobiol (2016) 0.76
FoxP1 marks medium spiny neurons from precursors to maturity and is required for their differentiation. Exp Neurol (2016) 0.76
Utility of Induced Pluripotent Stem Cells for the Study and Treatment of Genetic Diseases: Focus on Childhood Neurological Disorders. Front Mol Neurosci (2016) 0.76
Deriving striatal projection neurons from human pluripotent stem cells with Activin A. Neural Regen Res (2015) 0.76
In Vitro Differentiation of Human Neural Progenitor Cells Into Striatal GABAergic Neurons. Stem Cells Transl Med (2015) 0.76
Neural Conversion and Patterning of Human Pluripotent Stem Cells: A Developmental Perspective. Stem Cells Int (2016) 0.76
ESC-Derived BDNF-Overexpressing Neural Progenitors Differentially Promote Recovery in Huntington's Disease Models by Enhanced Striatal Differentiation. Stem Cell Reports (2016) 0.75
Differentiation of human telencephalic progenitor cells into MSNs by inducible expression of Gsx2 and Ebf1. Proc Natl Acad Sci U S A (2017) 0.75
How to make striatal projection neurons. Neurogenesis (Austin) (2015) 0.75
Can manipulation of differentiation conditions eliminate proliferative cells from a population of ES cell-derived forebrain cells? Neurogenesis (Austin) (2016) 0.75
Clinical Trials in a Dish: The Potential of Pluripotent Stem Cells to Develop Therapies for Neurodegenerative Diseases. Annu Rev Pharmacol Toxicol (2015) 0.75
Physiological, pathological, and engineered cell identity reprogramming in the central nervous system. Wiley Interdiscip Rev Dev Biol (2016) 0.75
Advances in Stem Cell Research- A Ray of Hope in Better Diagnosis and Prognosis in Neurodegenerative Diseases. Front Mol Biosci (2016) 0.75
Induction of DARPP-32 by brain-derived neurotrophic factor in striatal neurons in vitro is modified by histone deacetylase inhibitors and Nab2. PLoS One (2013) 0.75
hESC-derived neural progenitors prevent xenograft rejection through neonatal desensitisation. Exp Neurol (2016) 0.75
Induced Pluripotent Stem Cells in Huntington's Disease: Disease Modeling and the Potential for Cell-Based Therapy. Mol Neurobiol (2015) 0.75
STB-HO, a novel mica fine particle, inhibits the teratoma-forming ability of human embryonic stem cells after in vivo transplantation. Oncotarget (2016) 0.75
The Isotropic Fractionator as a Tool for Quantitative Analysis in Central Nervous System Diseases. Front Cell Neurosci (2016) 0.75
Niche-independent symmetrical self-renewal of a mammalian tissue stem cell. PLoS Biol (2005) 9.12
A gene network regulating lysosomal biogenesis and function. Science (2009) 7.17
Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature (2003) 5.31
Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord (2012) 5.12
Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet (2003) 4.76
Dopamine neuron systems in the brain: an update. Trends Neurosci (2007) 4.44
EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell (2003) 4.33
SUMO modification of Huntingtin and Huntington's disease pathology. Science (2004) 3.85
Microglia activated by IL-4 or IFN-gamma differentially induce neurogenesis and oligodendrogenesis from adult stem/progenitor cells. Mol Cell Neurosci (2005) 3.77
Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev (2010) 3.69
Infiltrating blood-derived macrophages are vital cells playing an anti-inflammatory role in recovery from spinal cord injury in mice. PLoS Med (2009) 3.68
Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism. Nature (2005) 3.53
Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21. Hum Mol Genet (2010) 3.34
The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain (2009) 3.03
Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol (2009) 2.93
The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain (2003) 2.81
New ISSCR guidelines underscore major principles for responsible translational stem cell research. Cell Stem Cell (2008) 2.61
Tests to assess motor phenotype in mice: a user's guide. Nat Rev Neurosci (2009) 2.60
L-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson's disease. Neuropsychologia (2003) 2.55
Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum Mol Genet (2007) 2.54
Surveying the literature from animal experiments. BMJ (2005) 2.51
A microRNA-based gene dysregulation pathway in Huntington's disease. Neurobiol Dis (2007) 2.41
Disintegration of the sleep-wake cycle and circadian timing in Huntington's disease. J Neurosci (2005) 2.34
Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry. J Neurosci (2003) 2.22
The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry (2013) 2.20
Role of brain-derived neurotrophic factor in Huntington's disease. Prog Neurobiol (2007) 2.17
A novel neuroprotective therapy for Parkinson's disease using a viral noncoding RNA that protects mitochondrial complex I activity. J Exp Med (2011) 2.10
The natural history of treated Parkinson's disease in an incident, community based cohort. J Neurol Neurosurg Psychiatry (2011) 2.08
Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Proc Natl Acad Sci U S A (2003) 2.05
Health-related quality of life in early Parkinson's disease: the impact of nonmotor symptoms. Mov Disord (2013) 1.98
Neural stem cell systems: physiological players or in vitro entities? Nat Rev Neurosci (2010) 1.97
Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann Neurol (2007) 1.95
Microglial activation in presymptomatic Huntington's disease gene carriers. Brain (2007) 1.93
The level of the transcription factor Pax6 is essential for controlling the balance between neural stem cell self-renewal and neurogenesis. PLoS Genet (2009) 1.92
Delayed post-ischaemic neuroprotection following systemic neural stem cell transplantation involves multiple mechanisms. Brain (2009) 1.89
Motor training effects on recovery of function after striatal lesions and striatal grafts. Exp Neurol (2003) 1.85
Pax6 controls cerebral cortical cell number by regulating exit from the cell cycle and specifies cortical cell identity by a cell autonomous mechanism. Dev Biol (2006) 1.84
Widespread disruption of repressor element-1 silencing transcription factor/neuron-restrictive silencer factor occupancy at its target genes in Huntington's disease. J Neurosci (2007) 1.77
Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET. Brain (2002) 1.75
Opinion: neural stem cell therapy for neurological diseases: dreams and reality. Nat Rev Neurosci (2002) 1.71
Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease. J Neurosci (2005) 1.68
Persistent inflammation alters the function of the endogenous brain stem cell compartment. Brain (2008) 1.67
L-DOPA disrupts activity in the nucleus accumbens during reversal learning in Parkinson's disease. Neuropsychopharmacology (2006) 1.66
Neural transplantation for the treatment of Parkinson's disease. Lancet Neurol (2003) 1.64
Striatal contributions to working memory: a functional magnetic resonance imaging study in humans. Eur J Neurosci (2004) 1.64
Long-term tripotent differentiation capacity of human neural stem (NS) cells in adherent culture. Mol Cell Neurosci (2008) 1.62
Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol (2011) 1.62
Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis. J Neurosci (2009) 1.59
REST controls self-renewal and tumorigenic competence of human glioblastoma cells. PLoS One (2012) 1.58
Cross-talk between neural stem cells and immune cells: the key to better brain repair? Nat Neurosci (2012) 1.55
Mutant huntingtin is present in neuronal grafts in Huntington disease patients. Ann Neurol (2014) 1.55
Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations. Lancet Neurol (2012) 1.54
Dopaminergic basis for deficits in working memory but not attentional set-shifting in Parkinson's disease. Neuropsychologia (2004) 1.54
Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study. Neurology (2013) 1.53
Synergy between immune cells and adult neural stem/progenitor cells promotes functional recovery from spinal cord injury. Proc Natl Acad Sci U S A (2006) 1.50
Weighing brain activity with the balance: Angelo Mosso's original manuscripts come to light. Brain (2013) 1.50
Catechol O-methyltransferase Val158Met genotype influences frontoparietal activity during planning in patients with Parkinson's disease. J Neurosci (2007) 1.50
Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. Brain (2013) 1.46
Observing Huntington's Disease: the European Huntington's Disease Network's REGISTRY. PLoS Curr (2010) 1.45
Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses. Hum Mol Genet (2002) 1.45
Molecular classification of breast carcinomas using tissue microarrays. Diagn Mol Pathol (2003) 1.43
Drug repositioning for Alzheimer's disease. Nat Rev Drug Discov (2012) 1.42
A genome wide linkage disequilibrium screen in Parkinson's disease. J Neurol (2005) 1.41
The emerging technologies of neural xenografting and stem cell transplantation for treating neurodegenerative disorders. Drugs Today (Barc) (2004) 1.40
The first reported generation of several induced pluripotent stem cell lines from homozygous and heterozygous Huntington's disease patients demonstrates mutation related enhanced lysosomal activity. Neurobiol Dis (2012) 1.35
Smaller intracranial volume in prodromal Huntington's disease: evidence for abnormal neurodevelopment. Brain (2010) 1.35
Progressive loss of BDNF in a mouse model of Huntington's disease and rescue by BDNF delivery. Pharmacol Res (2005) 1.35
Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study. Hum Brain Mapp (2011) 1.32
Patients beware: commercialized stem cell treatments on the web. Cell Stem Cell (2010) 1.32
Systematic assessment of BDNF and its receptor levels in human cortices affected by Huntington's disease. Brain Pathol (2007) 1.32
The role of REST in transcriptional and epigenetic dysregulation in Huntington's disease. Neurobiol Dis (2010) 1.32
Dopamine-induced proliferation of adult neural precursor cells in the mammalian subventricular zone is mediated through EGF. Proc Natl Acad Sci U S A (2009) 1.32
Neural stem/precursor cells for the treatment of ischemic stroke. J Neurol Sci (2007) 1.31
Human neural stem cells ameliorate autoimmune encephalomyelitis in non-human primates. Ann Neurol (2009) 1.30
The spectrum of nonmotor symptoms in early Parkinson disease. Neurology (2013) 1.29
Attentional control in Parkinson's disease is dependent on COMT val 158 met genotype. Brain (2008) 1.28
Regulation of stem cell therapies under attack in Europe: for whom the bell tolls. EMBO J (2013) 1.28
Neural grafting in Parkinson's disease Problems and possibilities. Prog Brain Res (2010) 1.28
The heterogeneity of idiopathic Parkinson's disease. J Neurol (2002) 1.28
Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease. J Neurol (2009) 1.27
Magnetic-resonance-based tracking and quantification of intravenously injected neural stem cell accumulation in the brains of mice with experimental multiple sclerosis. Stem Cells (2007) 1.27
Membrane trafficking and mitochondrial abnormalities precede subunit c deposition in a cerebellar cell model of juvenile neuronal ceroid lipofuscinosis. BMC Neurosci (2004) 1.27
Double dissociation between hippocampal and prefrontal lesions on an operant delayed matching task and a water maze reference memory task. Behav Brain Res (2006) 1.27
Myeloid microvesicles are a marker and therapeutic target for neuroinflammation. Ann Neurol (2012) 1.26
Transplanted neural stem/precursor cells instruct phagocytes and reduce secondary tissue damage in the injured spinal cord. Brain (2012) 1.26
Activation of invariant NKT cells by alphaGalCer administration protects mice from MOG35-55-induced EAE: critical roles for administration route and IFN-gamma. Eur J Immunol (2003) 1.25
Genetically induced adult oligodendrocyte cell death is associated with poor myelin clearance, reduced remyelination, and axonal damage. J Neurosci (2011) 1.24
Assessment of the relationship between pre-chip and post-chip quality measures for Affymetrix GeneChip expression data. BMC Bioinformatics (2006) 1.24
Neurogenesis in the R6/1 transgenic mouse model of Huntington's disease: effects of environmental enrichment. Eur J Neurosci (2006) 1.23
Habitual versus goal-directed action control in Parkinson disease. J Cogn Neurosci (2010) 1.22
Calcium homeostasis and mitochondrial dysfunction in striatal neurons of Huntington disease. J Biol Chem (2007) 1.21
Immune regulatory neural stem/precursor cells protect from central nervous system autoimmunity by restraining dendritic cell function. PLoS One (2009) 1.21
Neural stem cell transplantation in central nervous system disorders: from cell replacement to neuroprotection. Curr Opin Neurol (2012) 1.21
Comparison of incremental and accelerating protocols of the rotarod test for the assessment of motor deficits in the 6-OHDA model. J Neurosci Methods (2006) 1.20